# Encompass Health Corporation – Consensus ‘buy’ rating and 17.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/encompass-health-corporation-consensus-buy-rating-and-17.7-upside-potential/4121127658
- Published: 2023-09-19T13:32:51+01:00
- Author: Charlotte Edwards

**Encompass Health Corporation** which can be found using ticker (EHC) have now 
10 market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The range between the high target price and low target price is between
85 and 71 calculating the average target price we see $80.00. Given that the stocks
previous close was at $67.97 this now indicates there is a potential upside of 17.7%.
There is a 50 day moving average of $68.98 and the 200 day MA is $62.42. The total
market capitalization for the company now stands at 6.92B. The stock price is currently
at: 69.09 USD

 The potential market cap would be $8,150,606,717 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 20.75, revenue per share of 46.04
and a 6.67% return on assets.

Encompass Health Corporation is a provider of post-acute healthcare service. The
Company manages its operations through its inpatient rehabilitation segment. The
Company is the owner and operator of rehabilitation hospitals. It operates hospitals
in approximately 37 states and Puerto Rico, with concentrations in the eastern half
of the United States and Texas. The Company operates approximately 156 inpatient
rehabilitation hospitals. It provides specialized rehabilitative treatment on an
inpatient basis. The Company’s inpatient rehabilitation hospitals offer specialized
rehabilitative care across an array of diagnoses and deliver comprehensive patient
care services. It also provides rehabilitative care for patients recovering from
injury or illness, using advanced technology and treatments to maximize recovery.
Its hospitals provide a comprehensive interdisciplinary clinical approach to treatment
that leverages technologies and advanced therapies and leads to superior outcomes.

Share on: